QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 00:27 UTC · Public disclosure record

FMSTICKER

Fresenius Medical Care AG

NEUTRAL stock

Congress has disclosed 5 buys and 9 sells of FMS (Fresenius Medical Care AG) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

5
Buy
9
Sell
-4
Net
6
Active politicians

Round-trip watch Still on the books

Members who disclosed buying FMS and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Alan Armstrong 2026-03-30 $21.35 $22.47 +5.2% ↩ near entry

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Legislation Related Legislation

Recent bills in this stock's sector (). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

14 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Alan Armstrong Senate BUY Self 2026-03-30 113 days +15.6% $1K–$15K 99.1 ↗ eFD
Daniel Goldman House SELL Self · Daniel Goldman Grandchildren 1986 Trust > TLH ADR 2023-07-10 25 days — $1K–$15K
<0.1% of NW
75.9 ↗ filing
Dean Phillips House BUY Self 2021-01-11 28 days — $1K–$15K
<0.1% of NW
75.9 ↗ filing
Greg Gianforte House SELL Joint 2019-01-02 5 days — $100K–$250K 66.1 ↗ filing
Josh Gottheimer House SELL Joint 2018-12-21 7 days — $1K–$15K
<0.1% of NW
86.8 ↗ filing
Greg Gianforte House SELL Joint 2018-11-20 6 days — $50K–$100K 61.4 ↗ filing
Greg Gianforte House SELL Joint 2018-07-05 4 days — $15K–$50K 90.9 ↗ filing
Thomas MacArthur House SELL Joint 2017-10-26 6 days — $15K–$50K 20.1 ↗ filing
Thomas MacArthur House SELL Joint 2017-10-25 7 days — $1K–$15K 8.6 ↗ filing
Thomas MacArthur House SELL Joint 2017-05-01 31 days — $1K–$15K 10.6 ↗ filing
Thomas MacArthur House BUY Joint 2017-01-10 22 days — $1K–$15K 15.7 ↗ filing
Thomas MacArthur House BUY Joint 2017-01-09 23 days — $15K–$50K 48.0 ↗ filing
Thomas MacArthur House SELL Joint 2016-12-07 25 days — $15K–$50K 56.6 ↗ filing
Thomas MacArthur House BUY Joint 2016-02-22 8 days — $15K–$50K 90.9 ↗ filing

FAQ Common questions

How much has Congress traded FMS?

5 disclosed buys and 9 sells of FMS (Fresenius Medical Care AG) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade FMS?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.